Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:NRXP NASDAQ:OGI NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.90+2.8%$3.33$2.45▼$4.02$230.14M0.22369,316 shs720,563 shsNRXPNRx Pharmaceuticals$3.27-1.8%$2.77$1.10▼$6.01$64.78M1.74497,460 shs295,044 shsOGIOrganigram Global$1.88+0.5%$1.63$0.85▼$2.08$252.56M1.48747,790 shs577,658 shsVORVor Biopharma$37.46+2.1%$39.01$2.62▼$65.80$256.75M2.05389,991 shs390,504 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.08%-3.09%-17.06%-23.16%-16.32%NRXPNRx Pharmaceuticals-0.30%+14.43%+28.08%+0.60%+109.43%OGIOrganigram Global-2.09%+6.86%+14.02%+31.69%+7.47%VORVor Biopharma-6.57%+8.49%-10.10%-2.71%+178.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.90+2.8%$3.33$2.45▼$4.02$230.14M0.22369,316 shs720,563 shsNRXPNRx Pharmaceuticals$3.27-1.8%$2.77$1.10▼$6.01$64.78M1.74497,460 shs295,044 shsOGIOrganigram Global$1.88+0.5%$1.63$0.85▼$2.08$252.56M1.48747,790 shs577,658 shsVORVor Biopharma$37.46+2.1%$39.01$2.62▼$65.80$256.75M2.05389,991 shs390,504 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.08%-3.09%-17.06%-23.16%-16.32%NRXPNRx Pharmaceuticals-0.30%+14.43%+28.08%+0.60%+109.43%OGIOrganigram Global-2.09%+6.86%+14.02%+31.69%+7.47%VORVor Biopharma-6.57%+8.49%-10.10%-2.71%+178.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.00Hold$6.00106.90% UpsideNRXPNRx Pharmaceuticals 2.71Moderate Buy$34.50955.05% UpsideOGIOrganigram Global 1.00SellN/AN/AVORVor Biopharma 2.56Moderate Buy$113.83203.88% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, AVIR, VOR, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/1/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025AVIRAtea PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NRXPNRx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OGIOrganigram GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/25/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/24/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$55.009/10/2025NRXPNRx PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/8/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/8/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.008/25/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/19/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.00(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/AOGIOrganigram Global$117.47M2.15N/AN/A$2.07 per share0.91VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)NRXPNRx Pharmaceuticals-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)OGIOrganigram Global-$33.39M$0.0537.61N/AN/A2.86%-8.19%-5.79%12/17/2025 (Estimated)VORVor BiopharmaN/A-$273.20N/AN/AN/AN/AN/AN/AN/ALatest NRXP, AVIR, VOR, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31-$0.98-$0.67-$0.98N/AN/A8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17NRXPNRx PharmaceuticalsN/A0.110.11OGIOrganigram GlobalN/A2.591.42VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%NRXPNRx Pharmaceuticals4.27%OGIOrganigram Global34.63%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%NRXPNRx Pharmaceuticals19.00%OGIOrganigram Global0.09%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableNRXPNRx Pharmaceuticals219.81 million16.05 millionOptionableOGIOrganigram Global860134.34 million134.22 millionOptionableVORVor Biopharma1406.85 million65.45 millionNot OptionableNRXP, AVIR, VOR, and OGI HeadlinesRecent News About These CompaniesVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)4 hours ago | globenewswire.comVor Biopharma Inc. $VOR Shares Acquired by Goldman Sachs Group Inc.October 1 at 3:04 AM | marketbeat.comVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025September 29, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Raised to "Buy" at Stifel NicolausSeptember 26, 2025 | americanbankingnews.comVor Biopharma (NYSE:VOR) and Prime Medicine (NASDAQ:PRME) Critical SurveySeptember 26, 2025 | americanbankingnews.comVor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease PromiseSeptember 25, 2025 | seekingalpha.comVor Biopharma upgraded to Buy at Stifel on telitacicept prospectsSeptember 24, 2025 | msn.comStifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to BuySeptember 24, 2025 | marketbeat.comVor Biopharma Shares Rise After Appointment of Navid Khan as Medical Affairs ChiefSeptember 23, 2025 | marketwatch.comVor Bio Appoints Navid Z. Khan, Ph.D.September 23, 2025 | globenewswire.comComparing Vor Biopharma (NYSE:VOR) & Prime Medicine (NASDAQ:PRME)September 23, 2025 | americanbankingnews.comReprogrammed Interchange Llc Sells 447,278 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Price Down 8.6% After Insider SellingSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 SharesSeptember 19, 2025 | marketbeat.comVor Biopharma trading halted on Thursday, news pendingSeptember 19, 2025 | msn.comVor Biopharma trading halted, news pendingSeptember 19, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17, 2025 | prnewswire.comVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMSeptember 17, 2025 | globenewswire.comReprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in StockSeptember 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Most Upgraded Stocks in Q3: Good News for the S&P 500By Thomas Hughes | September 17, 2025Why Seagate Is Wall Street's New Favorite AI Infrastructure PlayBy Jeffrey Neal Johnson | September 18, 2025Ford Set to Outpace GM With Tariff Tailwinds and EPS MomentumBy Gabriel Osorio-Mazilli | September 24, 2025Beam Global Gets Buy Rating With 101% Upside PotentialBy Nathan Reiff | September 27, 2025Which National Chains Do People Wish Were in Their State? [2025 Survey]By MarketBeat Staff | September 30, 2025NRXP, AVIR, VOR, and OGI Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$2.90 +0.08 (+2.84%) Closing price 04:00 PM EasternExtended Trading$2.87 -0.03 (-1.03%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.NRx Pharmaceuticals NASDAQ:NRXP$3.27 -0.06 (-1.80%) Closing price 04:00 PM EasternExtended Trading$3.30 +0.02 (+0.76%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Organigram Global NASDAQ:OGI$1.88 +0.01 (+0.53%) Closing price 04:00 PM EasternExtended Trading$1.89 +0.01 (+0.53%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Vor Biopharma NYSE:VOR$37.46 +0.78 (+2.13%) Closing price 04:00 PM EasternExtended Trading$38.14 +0.68 (+1.82%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play General Dynamics Hits New Highs: Why It Might Keep Climbing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
